Selection of Program Targets Clause Samples
The 'Selection of Program Targets' clause defines the process and criteria by which specific objectives, benchmarks, or performance goals are chosen for a program. Typically, this clause outlines who is responsible for setting these targets, the timeline for their selection, and any factors or data that must be considered in the decision-making process. For example, it may require that targets align with organizational priorities or be based on past performance metrics. The core function of this clause is to ensure that all parties have a clear understanding of what the program aims to achieve, thereby providing direction and a basis for measuring success.
Selection of Program Targets. (a) As of the Effective Date, the Parties have selected [**] as the subject of the Program to be progressed by the Parties during the Research Term.
(b) Prior to [**], Roche shall have the right to propose, in accordance with the remainder of this Section 4.3, additional Targets directed to [**] until up to one (1) additional Target is accepted by Alnylam as a Program Target pursuant to Section 4.3(d) below. Notwithstanding anything in this Agreement to the contrary, Roche shall not have the right to propose any Blocked Target, VEGF or KSP for inclusion as a Program Target hereunder.
(c) Alnylam shall submit any additional Target proposed by Roche in accordance with clause (b) above to Novartis in accordance with Section 2.6 of the LCA. Alnylam hereby waives, and Roche shall not be required to [**] with respect to the Target proposed by Roche pursuant to this Section 4.3 which would otherwise have been payable to Alnylam pursuant to Section 2.6 of the LCA. If Roche submits multiple Targets simultaneously, then the Parties shall agree to present [**] to Novartis, unless the Parties otherwise mutually agree that such [**].
(d) Subject to Novartis’ rejection or waiver of each proposed additional Target pursuant to clause (c) above, if Alnylam provides, in its sole discretion, written approval of such proposed additional Target (such approval not to be unreasonably withheld by Alnylam), such Target shall be deemed a Program Target for all purposes hereunder.
(e) If Novartis or Alnylam (approval not to be unreasonably withheld by Alnylam) rejects any proposed Target, Roche shall have the right to propose that an additional Target meeting the requirements set forth in Section 4.3(b) be included in the Program. If Roche does not propose any additional Target for inclusion as a Program Target by [**], then Roche’s right to propose an additional Program Target pursuant to this Section 4.3 shall have no further force or effect, and the sole subject of the Program and the Collaboration shall remain [**]. Once the first such additional proposed Target is included in the Program, Alnylam shall have no obligation to waive, and Roche shall thereafter be obligated to [**], unless the Parties otherwise mutually agree that such [**] shall be waived.
(f) For purposes of clarity, while the Parties contemplate that Roche may use Alnylam Platform Patent Rights or Alnylam Platform Know-How under the LCA to perform activities with respect to the Program Target during the Term, an...
Selection of Program Targets. Within [**] after the Effective Date, the Joint Management Committee shall select, from the list of available genes provided by Lexicon to Organon prior to the Effective Date, [**] Program Targets in addition to the two Program Targets separately designated as of the Effective Date. [**]. In the event that the Joint Management Committee is unable, within the relevant time periods specified above, to reach agreement with respect to the designation of the full number of Program Targets contemplated hereby, Organon shall have the right, during the period of [**] thereafter, to designate any remaining Program Targets from the relevant list of available genes.
Selection of Program Targets